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I. INTRODUCTION
Historically, prescriptive authority has been reserved for physicians.1
However, in light of the heightened responsibilities of health care providers,
prescriptive authority has been expanded to include other groups such as
nurses and physician’s assistants.2 Pharmacists are the next group seeking
the right to prescribe medication through collaboration with other health care
providers.3 Most states provide some form of prescriptive authority to
pharmacists, though the specific authority varies from state to state.4
The expansion of the pharmacist’s role is not completely novel. The
pharmacist’s role expanded as early as the 1960s, when “[h]ospital
pharmacists consulted with physicians about appropriate drug therapy and

1
Phyllis Coleman & Ronald A. Shellow, Extending Physician’s Standard of Care to
Non-Physician Prescribers: The Rx For Protecting Patients, 35 IDAHO L. REV. 37, 46 (1998).
2
Id. at 45.
3
CENTERS FOR DISEASE CONTROL AND PREVENTION, ADVANCING TEAM-BASED CARE
THROUGH COLLABORATIVE PRACTICE AGREEMENTS: A RESOURCE AND IMPLEMENTATION
GUIDE FOR ADDING PHARMACISTS TO THE CARE TEAM 8 (2017).
4
Id.
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participating in initial prescription decisions.”5 Washington State pioneered
expanding prescribing rights to pharmacists in 1979, when the state passed a
law permitting pharmacists to prescribe under specific protocols with
physician supervision.6 Many states soon followed suit, imposing their own
various limitations such as additional training, restrictions, and heightened
physician supervision.”7 Although it was the first state to enact pharmacist
prescribing legislation, Washington has made few changes to its law since
then. Washington allows for broad “collaborative practice agreements,”
allowing limited prescriptive authority to pharmacists with physician
supervision.8 In California, the state Business & Professions Code describes
a new type of pharmacist license—the advanced practice pharmacist
license—which grants prescriptive authority to licensed pharmacists with
additional training under certain conditions.9 In this comment, I will
examine the background of the legislative and regulatory frameworks
governing prescriptive authority, as well as the underlying policies that these
laws seek to promulgate. I will then compare the legislation in both
Washington and California, arguing that there is a place for pharmacist
prescribers, but that the legislation is overbroad and must be constricted to
avoid unintended and potentially harmful consequences.
The health care community can avoid the aforementioned harmful
consequences by eliminating broad and vague delegations of power from a
physician to a pharmacist and increasing the legislation surrounding
pharmacist prescribing. Pharmacists should be required to receive further
advanced training in order to prescribe. However, this right to prescribe
should not be extended to include the right to diagnose, and states and
medical boards must legislate carefully in order to avoid this confusion of
duties. Finally, there must be more physician oversight over pharmacists
exercising their right to prescribe, including communication and review
requirements.
II. BACKGROUND
For many years, there has been tension in the health care provider
community over which groups should be granted the right to prescribe.10
Many physicians believe that only a trained physician should have the right
to prescribe medication to a patient.11 Physicians undergo extensive training
5
6
7
8
9
10
11

Coleman, supra note 1, at 65.
Coleman, supra note 1, at 65.
Coleman, supra note 1, at 65.
WASH. ADMIN. CODE § 246-863-100 (2018).
CAL. BUS. & PROF. CODE § 4052.6 (2018).
Coleman, supra note 1, at 58.
See, e.g., Anna Gorman, Pharmacists Increasingly Take On Clinical Roles, KAISER
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on diagnosis and patient care, and many believe they are best positioned to
decide what medication will help a sick patient.12 As a result of their training,
physicians are granted unrestricted prescriptive authority in all fifty states.13
Two groups of secondary providers—nurses and physician’s assistants—
began seeking expansion of their scope of practice around 1965.14 These
providers argue that they are able to diagnose and treat patients with
medication due to their extensive training.15 Secondary providers argue that
they provide the same quality of care as physicians, but at a lesser cost and
higher patient satisfaction.16 They also believe that allowing secondary
providers to have prescribing rights will improve health care access in
underserved populations.17 These groups believe the objections coming
from physicians are not based on concerns for patients but are rather
manifestations of a “turf war” between physicians and other health care
providers.18
Despite objections from physicians, legislators responded to these
requests by amending state laws to include diagnosing and prescribing in the
list of duties of nurse practitioners and physician’s assistants.19 As it
currently stands, all fifty states provide nurses and physician’s assistants with
prescriptive authority in some capacity.20 Some states limit prescriptions of
controlled substances, while others require direct supervision by a
physician.21
Many physicians have pushed back at the expansion of prescribing
rights to these secondary health care providers.22 Physicians argue that there
HEALTH NEWS (Feb. 11, 2014), https://khn.org/news/pharmacists-see-clinical-role-expand/;
Katy Grimes, Doctors Rip Idea of Nurses Playing Doctor, CALWATCHDOG, (Aug. 8, 2013),
https://calwatchdog.com/2013/08/08/doctors-rip-idea-of-nurses-playing-doctor/.
12
Coleman, supra note 1, at 52.
13
Coleman, supra note 1, at 46.
14
Coleman, supra note 1, at 59.
15
Coleman, supra note 1, at 48.
16
Coleman, supra note 1, at 48.
17
Coleman, supra note 1, at 48.
18
Coleman, supra note 1, at 48. There is little evidence to back up either group of
secondary practitioner’s claims, as they are often opinions or inferences. For example, some
secondary provider believe that physicians are “reacting to rising health care costs and
severely restricted third-party payor reimbursement by attempting to protect tasks
traditionally within their exclusive domain,” such as prescribing. But physicians hold that
these other providers lack the education and training necessary to safely prescribe. In fact,
physicians contend a primary reason these secondary providers are seeking prescribing
authority is to increase their income. Coleman, supra note 1, at 58.
19
Coleman, supra note 1, at 59.
20
Mary Beck, Improving America’s Health Care: Authorizing Independent Prescriptive
Privileges for Advanced Practice Nurses, 29 U.S.F. L. REV. 951, 954 (1995).
21
Id.
22
See Gorman, supra note 11 (“some physicians, however, are wary of pharmacists
doing too much on their own.”).
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is not enough collaboration and communication between secondary
providers and physicians.23 As a result of the lack of communication,
important information can slip through the cracks. Additionally, they
believe these groups do not receive enough training in diagnosing and
prescribing.24 Physician’s assistants and nurses are generally required to
receive more training before they can prescribe; in light of this training, they
are typically deemed competent to diagnose basic and obvious diseases and
conditions and treat accordingly.25 However, more complicated, nuanced, or
atypical ailments can cause concerns. Often, symptoms of a harmful disease
may mimic those of a more mild ailment.26 Diagnosis and subsequent
prescribing is further complicated in instances where several ailments coexist.27 In these cases, the absence of a comprehensive medical background
increases the probability that patients will be misdiagnosed.28 Because of
this, a non-physician prescriber may not know to refer a patient with a serious
disease if the provider believes it to be a basic ailment.29 There is also a
standard of care issue when non-physicians prescribe. Physicians believe
that if nurses and physician’s assistants retain the right to prescribe, they
should be held to the same standard in malpractice actions as a physician,
but nurses and physician’s assistants would prefer to be held to a lower
standard.30
Pharmacists face many of the same challenges and objections to nurses
and physician’s assistants prescribing, but nevertheless they became the next
group of health care providers to receive the coveted right to prescribe.31
Most states allow pharmacists some form of limited prescriptive authority.32
These states typically require a collaborative practice agreement or similar
arrangement with a practicing physician.33 A collaborative practice
agreement (“CPA”) is an agreement between a physician and a pharmacist,
nurse, or other health care provider that delegates some form of authority
from the physician to the aforementioned provider.34 These agreements can
go by other names as well, such as protocols, standing orders, collaborative
23

Gorman, supra note 11.
See Coleman, supra note 1, at 50.
25
Coleman, supra note 1, at 49–50.
26
Coleman, supra note 1, at 50.
27
Coleman, supra note 1, at 50.
28
Coleman, supra note 1, at 50.
29
Coleman, supra note 1, at 50.
30
Coleman, supra note 1, at 78–79.
31
See Gorman, supra note 11.
32
CENTERS FOR DISEASE CONTROL AND PREVENTION, supra note 3, at 8.
33
Collaborative Practice Agreements: Resources and More, NAT’L ALL.
PHARMACY ASS’NS., www.naspa.us/cpa (last visited Feb. 2, 2020).
34
Id.
24

OF

STATE
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care agreements, and others.35 A CPA is just one of several pathways by
which a pharmacist may gain prescriptive authority.36 A physician can
choose whether to enter into a CPA with a pharmacist and may delegate
some form of authority to the pharmacist.37 This authority can include the
initiation of medication, otherwise known as prescribing, as well as
modification or discontinuation of medication.38 Other possibilities include
the authority to substitute another drug in the same drug class for the
medication originally prescribed.39
Moreover, the agreement may be limited in setting or may contain a
requirement that the pharmacist prescribing a drug notifies the treating
physician within a certain time frame after doing so.40 The full range of
pharmacist prescriptive powers allowed by CPAs varies from state to state
and agreement to agreement.41 Some states only allow modification of
medication, but not initiation of a new drug therapy.42 Some states
specifically limit the classes of drugs that pharmacists may prescribe, while
others remain silent on class restrictions.43 Some of the most common
medications that are allowed to be prescribed are those that treat asthma,
hypertension, hyperlipidemia, and COPD.44 Although these are typical
examples of permitted pharmacist-prescribed medication, many states have
no explicit restrictions on drug classes that a pharmacist may prescribe.45
The pharmacist prescribing laws of Washington and California
represent two different eras of prescriptive law history. Washington’s statute
is vague, broad, and without a recent update.46 It is a representation of an era
35

CENTERS FOR DISEASE CONTROL AND PREVENTION, supra note 3, at 8.
Pharmacist Prescribing: Statewide Protocols and More, NAT’L ALL. OF STATE
PHARMACY ASS’NS., www.naspa.us/swp (last visited Feb. 2, 2020).
37
Collaborative Practice Agreements: Resources and More, supra note 33.
38
See, e.g., WASH. ADMIN. CODE § 246-863-100 (2)(c).
39
See N.D. ADMIN. CODE § 61-04-08-06(2) (2018).
40
Compare TEX. OCC. CODE § 157.101(b-1)(2) (2018) (limiting delegation authority to
hospitals, hospital-based clinics, and academic health care institutions), with WASH. ADMIN.
CODE § 246-863-100 (specifying no time limit in setting). See CAL. BUS. & PROF. CODE §
4052.2 (2018) (requiring notice within twenty-four hours).
41
See Pharmacist Prescribing: Statewide Protocols and More, supra note 36.
42
N.J. STAT. ANN. § 45:14-41 (2018) (allowing only for modification or discontinuation
of drug therapy by a pharmacist).
43
Compare 243 MASS. CODE REGS. § 2.12(4)(e)(6)(b) (2018) (limiting the types of
drugs that may be prescribed in community settings and disallowing controlled substance
prescriptions), with WASH. ADMIN. CODE § 246-863-100 (no language to restrict the classes
of drugs pharmacists may prescribe).
44
243 MASS. CODE REGS. § 2.12(4)(e)(6)(b).
45
See, e.g., WASH. ADMIN. CODE § 246-863-100 (no language to restrict the classes of
drugs pharmacists may prescribe); KY. REV. STAT. §§315.010 (no language regarding classes
of drugs a pharmacist may prescribe).
46
WASH. ADMIN. CODE § 246-863-100 (no agency filings affecting this section since
2003).
36
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when pharmacist prescribing law was murky and actual pharmacist
prescribers were uncommon. The law has remained unchanged despite the
widening landscape of prescriptive authority and the expansion of the role of
the pharmacist.47 California, a state known for progressive legislation,
represents the new era of expanded prescribing authority. In line with the
modern trend, California’s statute attempts to advance the rights and duties
of pharmacists.48 However, the statute recognizes that detailed parameters
and legislation must surround pharmacist prescribing if it is to become the
norm.49
III. ANALYSIS OF STATUTES
A. Washington
Washington’s Administrative Code has allowed pharmacists to enter
into CPAs, called Collaborative Drug Therapy Agreements (CDTAs), with
physicians since 1980.50 Pharmacists may exercise prescriptive authority in
accordance with written guidelines or protocols previously established and
approved by an authorized prescriber.51 These protocols must include a
statement of the types of diseases, drug categories involved, and the type of
prescriptive activity (e.g., modification or initiation of drug therapy)
authorized in each case.52 There is no statutory authority to limit the classes
or categories of drugs that physicians may allow pharmacists to prescribe.53
Under a CPA, a pharmacist can prescribe controlled substances with a Drug
Enforcement Administration number, and the pharmacist is not limited to
any specific setting (i.e. institutional).54 The protocol must include a
statement of the activities that the pharmacist is to follow in the course of
exercising prescriptive authority, including documentation of decisions
made and a plan to provide feedback to the authorizing practitioner
concerning specific decisions made.55 However, there is no statutorily
required time frame for communication between the primary provider and

47

Id.; Gorman, supra note 11.
CAL. BUS. & PROF. CODE § 4016.5 (2018); see Gorman, supra note 11.
49
See Diana Yap, The Saga of SB 493: Hernandez and California’s New Provider Status
Law, PHARMACY TODAY (Mar. 1, 2014), https://www.pharmacist.com/article/saga-sb-493hernandez-and-californias-new-provider-status-law.
50
See WASH. ADMIN. CODE § 246-863-100.
51
Id. at § 246-863-100(1).
52
Id. at § 246-863-100(2)(c)(i)(ii).
53
WASH. ADMIN. CODE § 246-863-100 (silent on limitations).
54
See DRUG ENFORCEMENT AGENCY, U.S. DEP’T OF JUSTICE, PRAC.’S MANUAL § 5
(2006).
55
WASH. ADMIN. CODE § 246-863-100(2)(d).
48
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the pharmacist upon initiation of medication.56 Additionally, there is no
language in the statute pertaining to additional training or residency
requirements.57
Currently, there are over 33,000 active CDTAs in the state of
Washington.58 Though CDTAs have been abundant in the state since 1979,
inquiries into their scope are more recent and compelling.59 In 2018, the
Washington Medical Commission sought a formal opinion from the state
Attorney General regarding the scope of pharmacists’ authority.60 The
request sought, in part, to clarify whether a pharmacist’s duties under a
CDTA included diagnosis.61 Additionally, the request inquired whether a
physician could delegate diagnosis responsibilities to a pharmacist under a
CDTA.62 Finally, the request asked if a pharmacist diagnosing a patient
pursuant to a CDTA constitutes an unlicensed practice of medicine.63 The
Commission took the position that the duty of a pharmacist does not include
diagnosis, and therefore a physician cannot delegate this responsibility.64
However, the response noted that the Commission does not acknowledge any
statutes or rules that govern the responsibilities or limitations of physician
delegation under a CDTA.65
In response to this request, the National Alliance of State Pharmacy
Associations (NASPA) and the National Community Pharmacist’s
Association (NCPA) submitted a joint letter to the state Attorney General’s
office.66 In the letter, NASPA and NCPA argued that Washington State
pharmacists prescribing pursuant to a CDTA must do so in accordance with
the terms agreed upon in the CDTA.67 If a prescriber includes diagnosing or
independent prescribing activities in the guidelines or protocols of the
CDTA, then pharmacists may do so per the terms of the agreement.68
NASPA and NCPA also asserted that Chapter 18.64 of the Washington
Administrative Code (WAC) governs the practice of pharmacy and it cannot
56

WASH. ADMIN. CODE § 246-863-100 (silent on communication time frame).
WASH. ADMIN. CODE § 246-863-100 (silent on additional training or education).
58
Letter from the Nat’l All. of State Pharmacy Ass’ns. & Nat’l Cmty. Pharmacists
Ass’n. to Jeff Even, Deputy Solic. Gen. (Aug. 9, 2018) (on file with author).
59
Id. at 2–3.
60
Letter from the Wash. Med. Comm’n to Bob Ferguson, Attorney Gen. 10 (Jun. 8,
2018) (on file with author).
61
Id. at 5.
62
Id.
63
Id.
64
Id.
65
Id. at 10.
66
See Letter from the Nat’l All. of State Pharmacy Ass’ns. & Nat’l Cmty. Pharmacists
Ass’n. to Jeff Even, Deputy Solic. Gen. 1 (Aug. 9, 2018) (on file with author).
67
Id. at 4.
68
Id. at 5.
57
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impose any limitations on non-pharmacists—including duties nonpharmacist prescribers are authorized to delegate to pharmacists.69 NASPA
and NCPA contended that pharmacists are limited in their scope of authority
by threat of litigation and ethical duty alone.70 The letter states that
“Pharmacists have an ethical duty to self-restrain from accepting any
delegation of patient care services beyond their individual competency.”71
The letter points out that since the establishment of the CDTA in
Washington, there have been no lawsuits questioning CDTA’s legal
authority or asserting patient harm caused by their use.72 As a result, the two
groups contend that there is no need for further regulatory restriction on the
use of CDTAs.73
The conflicting opinions between the Washington Medical
Commission, NASPA, and NCPA are further evidence of the need for state
restriction on the practice of pharmacy. The Washington Medical
Commission recognizes the vagueness of the statutes governing
pharmacists’ scope of practice.74 The Commission seeks to clarify the
overbroad statutory language that leaves patients at risk of receiving subpar
care. The NASPA and NCPA wrongfully rely on the lack of lawsuits as
evidence that the current system is working.75 However, as the patient
population and patient needs increase, physicians will be forced to look to
secondary providers to ease their burdens.76 The State must protect
pharmacists from broad delegations of duty that cannot be adequately
discharged. Further, allowing the pharmacy profession to regulate itself on
ethics alone is irresponsible. Such a regulatory scheme will pressure
pharmacists to accept more responsibility than qualifications can justify so
the needs of their supervising physicians are satisfied. Pharmacists will be
caught in an ethical conundrum between whether to help patients who need
care, or to acknowledge certain limitations and reject a physician’s delegated
duties.

69

Id.
Id. at 6.
71
Id. at 6.
72
Letter from the Nat’l All. of State Pharmacy Ass’ns. & Nat’l Cmty. Pharmacists
Ass’n. to Jeff Even, Deputy Solic. Gen. 3 (Aug. 9, 2018) (on file with author).
73
Id.
74
See Letter from the Wash. Med. Comm’n, supra note 60, at 3.
75
See Letter from the Nat’l All. of State Pharmacy Ass’ns., supra note 58.
76
Gorman, supra note 11 (“[H]ealth officials are looking for ways to ease the strain on
overloaded doctors, improve care and contain costs. With millions of people gaining coverage
under the nation’s health law, experts say pharmacists can fill gaps in primary care and help
avoid unnecessary hospital admissions.”).
70
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B. California
Before the introduction of the Advanced Practice Pharmacist license,
California pharmacists could only prescribe in accordance with a CPA
alongside a physician in an institutional setting.77 Institutional settings
include hospitals, nursing homes, and long-term care facilities—places
where interaction between all members of a patient’s health care team are
frequent.78 A pharmacist was required to complete clinical residency
training, or demonstrate clinical experience in direct patient care delivery,
prior to entering into a CPA.79 In 2014, California introduced the Advanced
Practice Pharmacist license.80 President of the California Chapter of the
American College of Emergency Physicians, Tom Sugarman, M.D., stated
that “[t]o ensure patient safety and quality of care, it’s critical to have the
physician as the point of contact for care.”81 Sugarman also noted his
particular concerns about the license’s creation of a new pharmacist class of
opioid prescribers in a time where over prescribing of such drugs is already
a highly volatile issue.82
C. Comparison
Because California’s Advanced Practice Pharmacist initiative faced
such opposition when it was first introduced, it was consequently amended
several times to ensure that it was limited and specific in its prescriptive
authority.83 These amendments ensured that while pharmacists could still
benefit from an expansion in their prescriptive authority, they could only do
so with specific and explicit limitations.84
California community
pharmacists seeking to enter into CPAs as Advanced Practice Pharmacists
are required to complete extra training on patient care and drug therapy
management.85 The law also requires communication between the
77

CAL. BUS. & PROF. CODE § 4052.2(a).
See id.
79
CAL. BUS. & PROF. CODE § 4052.2(d).
80
CAL. BUS. & PROF. CODE § 4016.5 (2018).
81
Grimes, supra note 11.
82
Grimes, supra note 11.
83
Yap, supra note 49.
84
See Yap, supra note 49.
85
CAL. BUS. & PROF. CODE § 4210 (2018). This further training requires the pharmacist
to satisfy two out of three of the following criteria: (1) earn certification in a relevant area of
practice, including, but not limited to, ambulatory care, critical care, geriatric pharmacy,
nuclear pharmacy, nutrition support pharmacy, oncology pharmacy, pediatric pharmacy,
pharmacotherapy, or psychiatric pharmacy, from an organization recognized by the
Accreditation Council for Pharmacy Education or another entity recognized by the board; (2)
complete a postgraduate residency through an accredited postgraduate institution where at
least 50 percent of the experience includes the provision of direct patient care services with
interdisciplinary teams; (3) have provided clinical services to patients for at least one year
78
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pharmacist and physician within 24 hours of initiating new medication.86
This is especially important in a community pharmacy setting, such as a
Walgreens or Rite Aid, where interactions with the primary physician and
pharmacist may be less frequent. Additionally, all CPAs require approval
from the state’s pharmacy board.87
Washington State’s Administrative Code allows for much broader
pharmacist authority and relies greatly on deference to the physician and
pharmacist.88 Though the Washington Medical Commission argues that the
law should not allow a pharmacist to prescribe, this is not clear from the
statute.89 NASPA and NCPA argue that the law allows for total delegation
by a physician of prescribing and diagnosing authority to a pharmacist in any
setting, if desired.90 Regardless of the true meaning behind the statute, it is
clear that further regulation and clarification are needed.91
The only requirement for specificity of the CDTA is a mandatory list
of the types of diseases, drugs, or drug categories covered by the agreement.92
This leaves much of the decision making up to the pharmacists if they choose
not to consult with their supervising physicians prior to writing a
prescription. The law includes no discussion of limitation in setting, granting
community pharmacists the same level of authority as institutional setting
pharmacists without any additional training or communication requirement.
Furthermore, there is no requirement for additional training for a pharmacist
seeking to enter into a CDTA, regardless of setting.
In regards to communication, the law states that the CDTA must
include “a plan for communication or feedback to the authorizing
practitioner concerning specific decisions made,” but does not include a time
frame for the pharmacist to report diagnoses or initiation of new medications
to the physician.93 Frequency of communication is left up to the pharmacist
and physician, which could result in delayed communication after initiation
of medication leading to patient harm. Unlike California’s law, the
under a collaborative practice agreement or protocol with a physician, advanced practice
pharmacist, pharmacist practicing collaborative drug therapy management, or health system.
86
CAL. BUS. & PROF. CODE § 4052.
87
CAL. BUS. & PROF. CODE § 4210.
88
See WASH. ADMIN. CODE § 246-863-100.
89
Letter from the Washington Medical Comm’n, supra note 60.
90
Letter from the Nat’l All. of State Pharmacy Ass’ns., supra note 58.
91
The Washington State Attorney General’s Office has yet to release a response to either
party.
92
WASH. ADMIN. CODE § 246-863-100(2)(c)(i)(ii). This is not an inclusive list. A
physician may, but is not required to, include specific drugs or drug categories, such as
amoxicillin, or antibiotics generally. If the physician chooses, he or she may authorize a
pharmacist to prescribe for a disease state, such as high blood pressure or asthma, with no
mention of drug classes or categories.
93
WASH. ADMIN. CODE § 246-863-100(2)(d).
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Washington law, allowing pharmacist prescribing through a CDTA, has not
been updated in recent years.94 As it stands, it seems the legislature is content
to rely on feedback from the medical field to initiate changes to the CDTA
law.95
IV. IMPLICATIONS OF EXPANDED AUTHORITY
A. Benefits of Expansion
Though some argue that pharmacists and other second level health care
providers should not have the right to prescribe, with the proper legislative
guidance, pharmacists can exercise their limited prescriptive authority safely
and effectively to the great benefit of the medical community.96 One of the
driving factors behind expanding prescribing rights has always been the need
to serve the growing patient population.97 Physicians alone cannot keep up
with the masses of patients who need medical care, and other groups of
health care providers can alleviate this burden.98 In medically underserved
populations, it may be too expensive or burdensome for patients to visit a
physician every time they need a prescription.99 Examples of these
underserved populations include both poor rural and inner-city Americans,
as well as the elderly.100 These populations might see their doctor once a
year but may see their community pharmacist weekly, allowing them to form
a close relationship with their local pharmacist. Due to the ease of access,
they may be more comfortable asking questions and more likely to make an
in-person visit in case of a problem.101
Additionally, many pharmacists believe they are practicing below their
degrees.102 Pharmacists practicing in retail drug stores spend the majority of
their time on activities that do not require a pharmacist license.103 A survey
94

WASH. ADMIN. CODE § 246-863-100.
See WSMA Weighs in as State Attorney General Considers Pharmacists’ Scope of
Practice,
WASH.
STATE
MED.
ASS’N,
(Aug.
8,
2018),
https://wsma.org/Shared_Content/News/Membership_Memo/20180808/wsma_weighs_in_a
s_state_attorney_general_considers_pharmacists_scope_of_practice. Without the inquiry by
Washington Medical Commission, it is unlikely that the Attorney General would have
addressed the issue raised. As of this article, the Attorney General has yet to issue an opinion
on the matter.
96
See, e.g., Coleman, supra note 1, at 67.
97
Gorman, supra note 11.
98
See Gorman, supra note 11.
99
See Coleman, supra note 1, at 55-58.
100
Coleman, supra note 1, at 55-58.
101
See Gorman, supra note 11.
102
See Jannet M. Carmichael & Janice A. Cichowlas, The Changing Role of Pharmacy
Practice - A Clinical Perspective, 10 ANN. HEALTH L. 179, 186 (2001).
103
Id. at 185.
95
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conducted by the National Association of Chain Drug Stores Education
Foundation showed that pharmacists were spending sixty-eight percent of
their time on processing orders and prescriptions, managing inventory, and
other miscellaneous activities that do not require a licensed pharmacist.104
The survey determined that pharmacists were spending only thirty-one
percent of their time on activities that actually require a licensed pharmacist,
including reviewing and interpreting prescriptions, assessing patients’ drug
therapy, and counseling patients.105
Although they may not attend medical school, pharmacists receive
highly technical training in drug therapy management.106 Pharm.D.
programs usually include four years of professional study, followed by two
to four years of preprofessional education.107 In their six to eight years of
study, Pharm.D. students take courses in biology, chemistry, pharmacology,
pharmacotherapy, patient assessment, and medical ethics.108 The students
also receive experience-based education to gain experience providing care
to patients through services such as immunizations, medication
management, chronic disease management, patient assessment, and many
others.109 Though pharmacists may not receive training specifically on
diagnosis and medication selection, by working with a physician,
pharmacists are more than capable of making decisions regarding patient
care and prescribing.
B. Hazards of Expansion
Many of the potential issues with pharmacist prescribing come from a
lack of communication between physician and pharmacist.110 It is unclear
how involved a physician needs to be in a CPA, as there are not always
specific requirements for meaningful communication and collaboration
beyond a notification when a pharmacist initiates a medication.111 This lack
of specificity creates a high risk of miscommunication or lack of
communication, especially in a community pharmacy where a pharmacist is
not working alongside a physician in the same hospital as nurses and

104

Id.
Id.
106
See Letter from the Nat’l All. of State Pharmacy Ass’ns., supra note 58.
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physician’s assistants typically do.112 Even for higher level secondary
prescribers, such as nurse practitioners, lack of communication is still a
pertinent issue that becomes more troublesome as prescribing rights are
expanded to more groups.113 In Collip v. Ratts, a physician entered into a
CPA with a nurse practitioner.114 The CPA required the physician to review
at least five percent of the nurse’s charts on a weekly basis and to document
her prescribing practices.115 The physician had entered into eleven other
CPAs and also maintained a ninety-hour-per-week medical practice; he
admitted that he only engaged in a limited review of the nurse’s notes.116 He
became concerned about the amount of narcotics that the nurse was
prescribing to her patients but never followed up.117 Ultimately, one of the
nurse’s patients, who had never been treated, seen, or heard of by the
physician, died as a result of multiple drug interactions.118 This tragedy
occurred in a situation where the nurse and physician were working in close
proximity – a practice that is much less common in a pharmacist-physician
relationship.119 Even more concerning is that nurse practitioners, despite the
advanced training they are required to have in order to prescribe, are still at
risk to make catastrophic mistakes without sufficient physician
supervision.120 Pharmacists are subject to this same risk, but without the
requirement of advanced training or sufficient physician communication.121
Pharmacists should be allowed to utilize some form of prescriptive
power. The current legislative landscape, however, leaves too much room
for over-delegation by the physician and too much discretion to the
pharmacist. As previously stated, pharmacists are not trained in diagnosis.122
The NASPA and NCPA are comfortable with a pharmacist in Washington
making a diagnosis and subsequently prescribing a medication if this is what
the physician has delegated under a CDTA.123 This is troubling, especially
in light of the fact that a pharmacist in that state is not required to receive
extra training in diagnosis, prescribing, or patient care in order to enter into
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a CDTA.124 The only limitation to the pharmacist’s authority is the
physician’s discretion in delegating and the pharmacist’s ethical code.125
This is a recipe for overprescribing and mis-prescribing of medication.
Extending prescribing rights to any secondary health care provider carries
these same risks.126
In Evans v. Griswold, an optometrist prescribed an antibiotic for a
patient that he diagnosed as suffering from a bacterial eye infection.127 The
patient’s condition did not improve, and the optometrist sent her for tests and
stopped treatment.128 The patient returned almost two weeks later because
her eye was worse, and the optometrist recommended she take the same
antibiotic for another ten days.129 Two days later, the patient consulted an
ophthalmologist who concluded that the patient was experiencing a toxic
reaction to the medication that had not been recognized by the optometrist.130
Similar to pharmacists, optometrists receive an advanced degree and
are able to prescribe some medication in a limited capacity but are not
considered medical doctors.131 An ophthalmologist is a medical doctor who
has completed college and at least eight years of additional medical training
and is licensed to practice medicine and surgery.132 It is not difficult to see
how a similar situation could easily arise between a pharmacist prescribing
for a simple infection in accordance with a CPA, only to find that the patient
experiences an unforeseen reaction. Even ordinarily benign drugs like
antibiotics or hormonal birth control have side effects which may affect
individuals in unusual ways.133 Pharmacists may not always have sufficient
knowledge to respond to these unexpected problems arising from their
prescriptions.134
A similar example is pharmacist-prescribed hormonal birth control.
Hormonal birth control is generally seen as innocuous, and many believe it
could someday be granted over-the-counter status by the FDA.135 Oregon
124
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and California have both passed laws allowing pharmacists to prescribe short
acting hormonal contraception to women without a visit to a physician.136
The pharmacist must first complete a five hour training module covering
information on contraception mechanisms of action and patient counseling
on issues such as pill adherence, side effects, and potential interactions.137
However, a statewide survey conducted in Oregon revealed that only thirtynine percent of pharmacists were interested in prescribing birth control.138
Most of the pharmacists in this minority group cited the need for further
training in general contraception information and identifying
contraindications before they would feel comfortable independently
prescribing.139 It seems that even a number of pharmacists are uncomfortable
with the level of authority they have been given by the legislature.140
Not all drugs in the same class or category are created equal, and not
all diseases can be treated by just one type of drug. A disease state or drug
class listed in a CPA may not give pharmacists enough direction on what to
prescribe, with the differences leading to small but potentially significant
effects for the patient.141 Additionally, granting pharmacists this discretion
will allow them to make choices between brands of drugs, which will
introduce them to the issues facing physician prescribers and pharmaceutical
companies. Pharmaceutical companies may decide to target their marketing
to pharmacists, who do not receive training on transparency and antikickback laws. As it stands, the Sunshine Act only requires that
pharmaceutical companies report their spending on primary health care
providers.142 Companies are not required to report spending on secondary
health care providers, including pharmacists, even if those pharmacists are
prescribers.143 This exemption creates a huge loophole that could be used by
Interest in Provision, 56.5 J. AM. PHARMACISTS ASS’N 521, 522 (2016).
136
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Patricia A. Marken & J. Stuart Munro, Selecting a Selective Serotonin Reuptake
Inhibitor: Clinically Important Distinguishing Features, 2 PRIMARY CARE COMPANION J.
CLINICAL PSYCHIATRY 205 (Dec. 2000).
For example, a physician may authorize a pharmacist to prescribe a selective serotonin
reuptake inhibitor (SSRI) to a patient with a diagnosis of depression. All SSRIs have the same
mechanism of action and are similarly efficacious for the treatment of depression. However,
individual patients may respond differently to the same SSRIs, and.individual pharmacologic
differences may make one SSRI more or less suited for a given patient.
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42 CFR § 403.902. The Sunshine Act requires that manufacturers of drugs and
medical devices that are reimbursable by federal health care programs to track and report to
the Centers for Medicare and Medicaid Services (CMS) all financial relationships with
physicians. The law aims to increase transparency and uncover potential conflicts of interest.
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pharmaceutical companies to avoid the system put in place to discourage
bribery of heath care providers.
This loophole is particularly significant in the context of the opioid
epidemic. There is great danger in introducing a new class of opioid
prescribers in a market already rampant with overprescribing.144 The
Department of Justice has increased scrutiny on offenders from every level
of the system in the opioid-saturated market.145 Physicians, pharmaceutical
companies and their representatives, and even pharmacists have been
targeted by lawsuits from both private citizens and the government.146 A
pharmacist able to prescribe opioids pursuant to a CPA or CDTA is now a
new target for opioid users, abusers, and eventually prosecutors. Opioid
users may use these new pharmacist prescribers to skip the trip to the
physician, leaving one less barrier to the addictive drugs.
There is also a question of liability and standard of care in expanding
prescribing rights. If a pharmacist makes a mistake while acting in
accordance with a CPA, the law is not always clear on whether it is the
pharmacist or the physician who will be held liable.147 The Court of Appeals
of Indiana addressed this issue in a case concerning a CPA between a nurse
practitioner and a physician.148 The court stated, “[i]f a doctor complied with
his or her review and oversight obligations . . . and sees nothing troubling,
and one of the patients is harmed by the negligence of the nurse practitioner,
the doctor has not breached the duty to that patient.”149 This suggests that so
long as the physician complies with the CPA he or she drafted, the physician
will not be liable.150 The liability will instead fall to the secondary health
care provider.151
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from a prescribing pharmacist.152 Currently, two different standards are
applied to secondary health care providers performing tasks traditionally
reserved to medical doctors, such as prescribing.153 Under the first and more
stringent standard, prescribing pharmacists are considered to be acting as
doctors, and are held to that same high standard of care.154 Courts generally
shy away from applying this higher standard to secondary providers.155 The
second lower standard provides that because of their limited education,
secondary providers should be held to the standard of care of a “reasonably
prudent professional of similar experience and training.”156 The standard
asks whether the health care provider exercised the specific knowledge and
skill of similar professionals.157 This allows each profession to set its own
standards on how it will be judged.158 However, if secondary health care
providers believe they are able to prescribe just as well as physicians without
sacrificing patient safety, their argument against holding them to a
physician’s standard of care is illogical.159 This “similar professional” rule
lowers the bar for prescription errors and other functions traditionally within
the exclusive domain of a physician.160
C. Suggestions for Legislative Reform
It is clear that this area of the law needs further regulation and
clarification. It is not sufficient that the legislature defers to the medical
community to initiate change. The medical community is not able to agree
on the best path for pharmacist prescribing, or if it should even exist at all.
With so much discord between physicians and secondary prescribers, the
legislature needs to act as a neutral third party to determine what is truly in
the best interest of the people. Collaboration between different healthcare
providers can reduce healthcare costs and improve patient outcomes.161
However, pharmacists in community settings find this collaboration to be
152
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particularly challenging as they have great difficulty communicating with
the delegating physician.162 Some physicians report a lack of trust between
themselves and community pharmacists as compared to institutional
pharmacists.163 Other physicians report that their limited communications
with pharmacists outside their own practice are impersonal and often
unclear.164 This lack of trust and clarity can be combatted by frequent,
meaningful, and mandatory communications between physicians and
pharmacists entering into a CPA.
There must be a guarantee that pharmacists and physicians will
communicate about the patients being treated. It seems many physicians and
pharmacists want this level of effective communication, but simply need
assistance from the legislature or state boards in order to achieve it.165 At the
very least, state pharmacy boards should implement communication
requirements for CPAs. In addition, state legislators could set statewide
minimum standards for communication between physicians and pharmacists
entering a CPA. This will ensure actual collaboration between the physician
and pharmacists, as the legislature intended, and not just pharmacists
prescribing independently under the “oversight” of an absentee physician.
There also should be limitations, either implemented by state boards of
pharmacy or statute, on the types of medications pharmacists may prescribe.
Any substance with a high potential for abuse, including opioids and other
Schedule II controlled substances, should be excluded from a pharmacist’s
prescriptive authority.166 These drugs can cause severe psychological or
physical dependence, especially when over or mis-prescribed.167 Therefore,
patients should be required to visit a physician to obtain a prescription. At
the very least, if the state is not comfortable creating a banned drugs list, the
legislature should require that a CPA list the specific drugs a pharmacist can
prescribe for a specific diagnosis. The pharmacist should not have the
discretion to choose between different drugs in the same class or category.
If the pharmacist wishes to make a change or is unsure of a diagnosis, he or
she should be required to either contact the physician prior to making a
change or refer the patient back to the physician. Additionally, a pharmacist
should not have the authority to diagnose a patient simply because a
physician has delegated said authority. In order to create any truly effective
regulations surrounding pharmacist prescribing, clarification to the law
162
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regarding physician delegation under a CDTA is required. Specifically, the
ability to diagnose patients should be unassignable to a pharmacist and
should remain solely with the supervising physician.
Finally, further training should be required for pharmacists seeking
prescribing rights under a CPA. Unlike nurses and physician’s assistants,
pharmacists do not receive training in patient assessment and diagnoses in
their education. A short, one-day training course or an entirely online course
are both insufficient methods in preparing a pharmacist for prescribing
medication. If pharmacists wish to prescribe under a CPA, they should be
required to undergo an extensive and meaningful training program.
California’s Advanced Practice Pharmacist license, which requires extensive
training in patient care and clinical services, can serve as a model to other
states looking to expand prescribing rights.168
V. CONCLUSION
Pharmacists are on the front lines of patient care and are positioned to
effectively prescribe medications if regulated properly. Most states,
including Washington and California, are on board with granting this group
of providers broader authority to implement patient care regimens.169 These
states recognize the potential pharmacists have to increase patient
satisfaction and promote positive health outcomes.170
Washington was one of the first states to allow for pharmacist
prescribing under a CDTA, and the practice has become immensely popular
throughout the state.171 California recently introduced a new advanced
pharmacist license that allows for pharmacist prescribing under a CPA so
long as the pharmacist meets the heightened license requirements.172
However, granting pharmacists broad and undefined prescriptive authority
could result in disaster. The profession cannot be allowed to regulate itself
entirely. With physicians busier than ever, it is too easy for communication
to fall to the wayside and for pharmacists to be saddled with more than they
are qualified to accomplish. The state legislature must regulate prescriptive
authority to ensure adequate communication about patients and initiation of
medication. The state must also ensure that physician delegation is limited
to correspond with a pharmacist’s training and education level. Physicians
should be prevented from assigning diagnosing duties to a pharmacist, and
pharmacists should be prevented from accepting such duties. Additionally,
all Collaborative Practice Agreements need to have specific requirements,
168
169
170
171
172
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set by the state legislature, limiting the discretion of the pharmacist to an
appropriate level. Pharmacists seeking prescribing rights in any regard
should be required by the state to undergo further advanced training in
patient interaction, diagnosis, and prescribing in order to reduce the risk of
patient harm. Without these changes, problems of overprescribing and misprescribing will continue to rise, pharmacists will hesitate to utilize their
prescriptive power, and underserved populations will continue to suffer from
a lack of care.

